Roivant Sciences (NASDAQ:ROIV – Get Rating) will post its quarterly earnings results before the market opens on Tuesday, June 28th. Analysts expect Roivant Sciences to post earnings of ($0.23) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Shares of NASDAQ ROIV opened at $4.38 on Tuesday. Roivant Sciences has a 12 month low of $2.52 and a 12 month high of $16.76. The company has a quick ratio of 14.23, a current ratio of 14.23 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $3.84 and a 200-day simple moving average of $5.58.
In other news, COO Eric Venker sold 80,045 shares of the company’s stock in a transaction dated Friday, March 25th. The shares were sold at an average price of $5.06, for a total value of $405,027.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Rakhi Kumar sold 7,281 shares of the company’s stock in a transaction dated Friday, March 25th. The stock was sold at an average price of $5.06, for a total transaction of $36,841.86. The disclosure for this sale can be found here. Insiders sold a total of 480,878 shares of company stock worth $2,011,421 in the last three months.
ROIV has been the subject of several research analyst reports. Cantor Fitzgerald assumed coverage on Roivant Sciences in a research note on Friday, April 29th. They issued an “overweight” rating and a $15.00 price objective for the company. The Goldman Sachs Group reduced their target price on Roivant Sciences from $15.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, May 24th. Finally, SVB Leerink initiated coverage on shares of Roivant Sciences in a research note on Monday, May 23rd. They issued an “outperform” rating and a $6.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Roivant Sciences presently has an average rating of “Buy” and a consensus price target of $11.86.
Roivant Sciences Company Profile (Get Rating)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.